AUTERI, GIUSEPPE
 Distribuzione geografica
Continente #
NA - Nord America 207
EU - Europa 67
AS - Asia 33
SA - Sud America 10
AF - Africa 2
Totale 319
Nazione #
US - Stati Uniti d'America 194
IT - Italia 27
CA - Canada 12
JP - Giappone 12
GB - Regno Unito 10
CN - Cina 8
CO - Colombia 8
CH - Svizzera 5
FR - Francia 5
IN - India 5
PL - Polonia 5
DE - Germania 4
ES - Italia 3
TW - Taiwan 3
AT - Austria 2
BR - Brasile 2
ID - Indonesia 2
JO - Giordania 2
LV - Lettonia 2
CZ - Repubblica Ceca 1
DK - Danimarca 1
EG - Egitto 1
LT - Lituania 1
MX - Messico 1
MY - Malesia 1
RU - Federazione Russa 1
ZA - Sudafrica 1
Totale 319
Città #
Houston 22
Santa Cruz 22
Ann Arbor 14
Fairfield 14
Ashburn 10
Buffalo 9
Bogotá 8
Bologna 7
Cambridge 6
Seattle 6
Southend 4
Marcus Hook 3
Marseille 3
San Diego 3
Woodbridge 3
Bengaluru 2
Brockville 2
Chicago 2
Chongqing 2
Ferrara 2
Florence 2
Fremont 2
Gurgaon 2
Hangzhou 2
Jakarta 2
Lake Forest 2
Milpitas 2
Nardò 2
Ottawa 2
Ozarow Mazowiecki 2
Philadelphia 2
Polska 2
Riga 2
Sagamihara 2
Shizuoka 2
Taipei 2
Toronto 2
Atlanta 1
Bangalore 1
Beijing 1
Boston 1
Capo D'orlando 1
Chantilly 1
Clearwater 1
Columbus 1
Cuauhtémoc 1
Genova 1
Herndon 1
Kuala Lumpur 1
Las Vegas 1
Lindsay 1
Los Angeles 1
Madrid 1
Mettmach 1
Montecatini Terme 1
Mountain View 1
Nanchang 1
Napoli 1
New York 1
No 1
North Wales 1
Paris 1
Parla 1
Portland 1
Provo 1
Riva 1
Saint Petersburg 1
Salt Lake City 1
San Francisco 1
San Jose 1
Santa Clara 1
Settimo Torinese 1
Silverton 1
Torun 1
Uster 1
Washington 1
Wilmington 1
Yuma 1
Totale 219
Nome #
null, file e1dcb336-5e2c-7715-e053-1705fe0a6cc9 184
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms, file e1dcb335-d839-7715-e053-1705fe0a6cc9 48
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis, file e1dcb337-834e-7715-e053-1705fe0a6cc9 48
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells, file e1dcb332-6313-7715-e053-1705fe0a6cc9 29
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎, file e1dcb336-e7c0-7715-e053-1705fe0a6cc9 8
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera, file e1dcb338-acec-7715-e053-1705fe0a6cc9 7
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera, file e1dcb338-ff8c-7715-e053-1705fe0a6cc9 3
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS, file e1dcb332-6317-7715-e053-1705fe0a6cc9 2
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years., file e1dcb334-6b8c-7715-e053-1705fe0a6cc9 1
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib., file e1dcb334-7040-7715-e053-1705fe0a6cc9 1
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis, file e1dcb334-7501-7715-e053-1705fe0a6cc9 1
Totale 332
Categoria #
all - tutte 469
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 469


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192 0000 00 01 1000
2019/20206 0000 00 00 2121
2020/202183 4252 21 28 1216920
2021/2022194 11111138 264 1014 12123312
2022/202347 88265 00 00 0000
Totale 332